These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 33750072)

  • 1. Neurotoxicity Biology and Management.
    Danish H; Santomasso BD
    Cancer J; 2021 Mar-Apr 01; 27(2):126-133. PubMed ID: 33750072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
    Yang C; Nguyen J; Yen Y
    J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
    Gu T; Hu K; Si X; Hu Y; Huang H
    WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
    Siegler EL; Kenderian SS
    Front Immunol; 2020; 11():1973. PubMed ID: 32983132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines in CAR T Cell-Associated Neurotoxicity.
    Gust J; Ponce R; Liles WC; Garden GA; Turtle CJ
    Front Immunol; 2020; 11():577027. PubMed ID: 33391257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
    Ruff MW; Siegler EL; Kenderian SS
    Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.
    Schroeder T; Martens T; Fransecky L; Valerius T; Schub N; Pott C; Baldus C; Stölzel F
    Intensive Care Med; 2024 Sep; 50(9):1459-1469. PubMed ID: 39172238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist.
    Ong SY; Baird JH
    J Intensive Care Med; 2024 Oct; 39(10):929-938. PubMed ID: 37899577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological Complications of CAR T Cell Therapy.
    Landry K; Thomas AA
    Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe persistent neurotoxicity associated with CAR T therapy in children.
    Andrew EC; Hughes D; Gilsenan M; Mignone C; Khaw SL; Wang SS
    Br J Haematol; 2023 Nov; 203(4):651-655. PubMed ID: 37528536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
    Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H
    J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
    Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y
    J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicities following CAR-T therapy for hematological malignancies.
    Hernani R; Benzaquén A; Solano C
    Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
    Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
    Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
    Walton ZE; Frigault MJ; Maus MV
    Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.